Investor Relations
Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Upcoming Expiration of the Redemption Lock-up Period of GDRs
Time：2023-01-13
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Setting Up of a Joint Venture with Its Controlled Subsidiary Livzon Group
Time：2022-12-12
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Co-Investment with Livzon Group, the Controlled Subsidiary
Time：2022-11-28
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2022 Fourth Extraordinary General Meeting
Time：2022-11-18
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Approval Notice for Clinical Trial on Ilaprazole Tablets of Enteric-Coated Pellets
Time：2022-11-03
Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2022 Fourth Extraordinary General Meeting
Time：2022-10-26
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Plan for the Repurchase of Shares of the Company by Means of Centralized Bidding Transactions
Time：2022-10-16
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate for Tobramycin Inhalation Solution
Time：2022-10-14
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate for Acetylcysteine Solution for Inhalation
Time：2022-10-14
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Company's Drugs Approved for Registration in Indonesia
Time：2022-09-27
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.